期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Brentuximab vedotin(SGN-35)治疗CD30阳性复发难治淋巴瘤的最新进展 被引量：3

下载PDF
导出
摘要 20世纪90年代末期,随着利妥昔单抗和曲妥珠单抗在抗肿瘤领域的应用,单克隆抗体的发展逐渐成为大家关注的热点。利妥昔单抗是第1个获批上市的单克隆抗体,无论单药还是在联合化疗方面都取得了良好的疗效。然而单抗本身的疗效却不够稳定和持久,尤其是在单药应用时。
作者 王潇潇 黄慧强
机构地区 中山大学肿瘤防治中心华南肿瘤学国家重点实验室内科
出处 《广东医学》 CAS CSCD 北大核心 2013年第3期470-472,共3页 Guangdong Medical Journal
关键词 CD30阳性 复发难治 淋巴瘤 利妥昔单抗 单克隆抗体 治疗 曲妥珠单抗 联合化疗
分类号 R733.4 [医药卫生—肿瘤]
  • 相关文献

参考文献23

  • 1CHIARLE R, PODDA A, PROLLA G, et al. CD30 in normal and neoplastic cells[J]. Clin Immunol, 1999, 90(2) : 157 -164.
  • 2FRANCISCO J A, CERVENY C G, MEYER D L, et al. cAC10 - vcMMAE, an anti -CD30 -monomethyl auristatin E conjugate with potent and selective antitumor activity[ J]. Blood, 2003, 102 (4) : 1458 - 1465.
  • 3OKELEY N M, MIYAMOTO J B, ZHANG X, et al. Intracellular activation of SGN - 35, a potent anti - CD30 antibody - drug con- jugate[J]. Clin Cancer Res, 2010, 16(3): 888 -897.
  • 4SENTER P D. Potent antibody drug conjugates for cancer therapy [J]. Curr Opin Chem Biol, 2009, 13(3) : 235 -244.
  • 5YOUNES A, BARTLETT N L, LEONARD J P, et al. Brentux- imab vedotin ( SGN - 35 ) for relapsed CD30 - positive lymphomas [J]. NEnglJMed, 2010, 363(19): 1812-1821.
  • 6KATZ J, JANIK J E, YOUNES A. Brentuximab Vedotin ( SGN - 35) [J]. Clin Cancer Res, 2011, 17(20): 6428 -6436.
  • 7FANALE M, BARTLETT N L, FORERO TORRES A, et al. The antibody - drug conjugate brentuximab vedotin ( SGN - 35 ) in- duced multiple objective responses in patients with relapsed or re- fractory CD30 - positive lymphomas in a phase 1 weekly dosing study. ASH Annual Meeting Abstracts [ J]. Blood, 2009, 114 (22) : 2731.
  • 8ANSELMO A P, CAVALIERI E, OSTI F M, et al. Intermediate stage Hodgkin's disease: preliminary results on 210 patients trea- ted with four ABVD chemotherapy cycles plus extended versus in- volved field radiotherapy [ J ]. Anticancer Res, 2004, 24 ( 6 ) : 4045 - 4050.
  • 9AVIGDOR A, BULVIK S, LEVI I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early - inter- im PET/CT scan is an effective regimen for advanced high - risk Hodgkin's lymphoma[ J]. Ann Oncot, 2010, 21 ( 1 ) : 126 - 132.
  • 10DIEHL V, FRANKLIN J, HASENCLEVER D, et al. BEACOPP, a new dose -escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced- stage Hodgkin's lympho- ma: interim report from atrial of the German Hodgkin's Lymphoma Study Group[J]. J Clin Oncol, 1998, 16(12): 3810-3821.

同被引文献29

  • 1孔蕴毅,王坚,束木娟,孙孟红,施达仁,许越香,孔今城.原发性皮肤间变性大细胞淋巴瘤T细胞γ受体、IgH基因重排[J].临床皮肤科杂志,2005,34(1):3-6. 被引量：6
  • 2Willemze R, Jaffe ES, Burg G, et al. WHO -EORTC classification for cutaneous lymphomas [ J ]. Blood, 2005, 105 ( 10 ) : 3768 - 3785.
  • 3Bekkenk MW, Geelen FA, Van Voorst Vader PC, et al. Primary and seoondary cutaneous CD30 ( + ) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long - term follow - up data of 219 patients and guidelines for diagnosis and treatment[J]. Blood, 2000, 95(12) : 3653 -3661.
  • 4Kim YH, Willemze R, Pimpinelll N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fun- goides and Sezary syndrome : a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treat- ment of Cancer (EORTC) [ J ]. Blood, 2007, 110 ( 2 ) : 479 - 484.
  • 5Liu HL, Hoppe RT, Kohler S, et al. CD30 cutaneous lympho- proliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastie large cell lymphoma [J]. J Am Acad Dermatol, 2003, 49(6) : 1049 -1058.
  • 6Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30 positive lymphoproliferative disorders: lymphom- atoid papulosis and primary cutaneous anaplastic large - cell lym- phoma [ J ]. Blood, 2011, 118 ( 15 ) : 4024 - 4035.
  • 7Beljaards RC, Kaudewitz P, Berti E, et al. Primary cutaneous CD30 -positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Mul- ticenter Study of 47 patients [ J ]. Cancer, 1993, 71 (6) : 2097 - 2104.
  • 8Paulli M, Berti E, Rosso R, et al. CD30/Ki - 1 - positive lym- phoproliferative disorders of the skin clinicopathologic correla- tion and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group[ J]. J Clin Oncol, 1995, 13 (6) : 1343 - 1354.
  • 9Brice P, Cazals D, Mounier N, et al. Primary cutaneous large - cell lymphoma: analysis of 49 patients included in the LNH87 pro- spective trial of polychemotherapy for high - grade lymphomas. Grouped' Etude des Lymphomes de 1' Aduhe [ J ]. Leukemia, 1998, 12(2) : 213 -219.
  • 10Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ ALK: a distinct clinicopathologic entity[ J]. Blood, 1995, 86 (5): 1954 -1960.

引证文献3

二级引证文献5

广东医学
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部